Here, we present first evidence that in an in vitro model mimicking GCT of mixed histology, brentuximab vedotin exerts potent antiproliferative and pro‐apoptotic activity against both CD30‐positive as well as CD30‐negative GCT subsets. Here, TNFRSF8 is linked to granular cell tumor.